JP Morgan initiated coverage on Upstream Bio with a new price target
$UPB
Biotechnology: Pharmaceutical Preparations
Health Care
JP Morgan initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $38.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | $75.00 | Overweight | Piper Sandler |
| 11/5/2024 | $38.00 | Overweight | JP Morgan |
| 11/5/2024 | Outperform | William Blair | |
| 11/5/2024 | Buy | TD Cowen |
4 - Upstream Bio, Inc. (0002022626) (Issuer)
4 - Upstream Bio, Inc. (0002022626) (Issuer)
4 - Upstream Bio, Inc. (0002022626) (Issuer)
SC 13G - Upstream Bio, Inc. (0002022626) (Subject)
SC 13D - Upstream Bio, Inc. (0002022626) (Subject)
SC 13G - Upstream Bio, Inc. (0002022626) (Subject)
Piper Sandler initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $75.00
JP Morgan initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $38.00
William Blair initiated coverage of Upstream Bio with a rating of Outperform
WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr
– Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – – Top-line data from Phase 2 clinical trial of verekitug in patients with severe asthma now expected in the first half of 2026 – – First patient in Phase 2 clinical trial of verekitug in patients with chronic obstructive pulmonary disease to be dosed in mid-2025 – WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the first quarter ended Mar
– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 – – Completed upsized IPO with gross proceeds of approximately $293 million, extending runway through 2027 – WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a summary of recent business highlights. Upstream is developing verekitug, the only monoclonal
WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr
WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company has appointed Allison Ambrose, J.D. as General Counsel. Ms. Ambrose is a senior legal leader with more than 15 years of experience providing counsel on a wide range of matters including corporate governance, securities law and compliance, and capital markets and corporate development transactions. Ms. Ambrose will oversee all aspects of Upstream's legal function and join the Company's executive leadership team. "I am thrilled to welcome Allison to
4 - Upstream Bio, Inc. (0002022626) (Issuer)
4 - Upstream Bio, Inc. (0002022626) (Issuer)
4 - Upstream Bio, Inc. (0002022626) (Issuer)
10-Q - Upstream Bio, Inc. (0002022626) (Filer)
8-K - Upstream Bio, Inc. (0002022626) (Filer)
DEFA14A - Upstream Bio, Inc. (0002022626) (Filer)